Drug Profile


Alternative Names: Apatinib mesylate; YN-968-D1

Latest Information Update: 15 Feb 2017

Price : $50

At a glance

  • Originator Advenchen Laboratories LLC
  • Developer Bukwang Pharmaceutical; Fudan University Shanghai Cancer Center; Jiangsu Hengrui Medicine Co.; LSK Biopharma
  • Class Amides; Antineoplastics; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Proto oncogene protein c ret inhibitors; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gastric cancer
  • Phase III Hepatocellular carcinoma; Non-small cell lung cancer
  • Phase II Breast cancer; Colorectal cancer; Solid tumours

Most Recent Events

  • 26 Jul 2016 LSK BioPharma plans a pivotal phase III trial for Gastric cancer in USA, European Union, Japan, Korea and Taiwan
  • 20 Jul 2016 Phase-II clinical trials in Solid tumours in South Korea, USA (PO) (Advenchen Laboratories pipeline, July 2016)
  • 01 Jul 2016 Jiangsu HengRui Medicine Co. initiates a phase I pharmacokinetics trial in Healthy volunteers in China (PO, Tablet) (NCT02836171)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top